Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
The current Regeneron(REGN) stock price is $802.01, with a market capitalization of 82.57B. The stock trades at a price-to-earnings (P/E) ratio of 19.24 and offers a dividend yield of 0.48%.
During the trading session on 2026-10-15, Regeneron(REGN) shares reached a daily high of $809.49 and a low of $787.51. At a current price of $802.01, the stock is +1.8% higher than the low and still -0.9% under the high.
Trading volume for Regeneron(REGN) stock has reached 511.68K, versus its average volume of 668.66K.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $564.00.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $564.00.
REGN News
...
has delivered solid long term gains for shareholders over the past five years, and a fresh run of clinical and partnership news has pushed investors to reassess...
UBS upgraded Regeneron (REGN) to Buy from Neutral with a price target of $978, up from $660, after assuming coverage of the name. The shares at current levels a...
Analyst ratings
65%
of 31 ratingsMore REGN News
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's ear...
Regeneron (REGN) Pharmaceuticals announced 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru in adults with fibrodysplasia ossificans progressiva...
Regeneron Pharmaceuticals expanded its long running alliance with Sanofi, securing a US$1b upfront payment and sharing rights to four new long acting immunology...
Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.